Cargando…
Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
SIMPLE SUMMARY: Approximately 80% hepatocellular carcinoma (HCC) patients are in intermediate or advanced stages at diagnosis and have lost the chance of curative surgery, resulting in poor prognosis. Lenvatinib was approved in 2018 as a first-line treatment for unresectable HCC. The aim of this stu...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688932/ https://www.ncbi.nlm.nih.gov/pubmed/36428618 http://dx.doi.org/10.3390/cancers14225525 |